Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591
antibody in combination with docetaxel chemotherapy against metastatic, castrate-resistant
prostate cancer.